Real-Life Effectiveness and Tolerability of Brivaracetam in Focal to Bilateral and Primary Generalized Tonic-Clonic Seizures

Table 3

Clinical and treatment-related factors associated with response and seizure freedom rates for FBTCS/GTCS during follow-up.

	3 months				6 months				12 months
	Seizure-free		Responder		Seizure-free		Responder		Seizure-free		Responder
	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes
Univariate analysis
Sex, male	43.3%	52.2%	36.4%	53.3%	51.5%	49.3%	53.8%	48.7%	32%	55.1%	31.3%	52.6%
Age	31.9	37.4	34.9	35.9	31.2	38.7	31.3	38	28	37.5	25.4	37.0
Age at onset, years, mean	15.4	24.5	16.1	23.3	16.1	25.9	15.9	25.1	13.6	25.6	12.4	24.5
Epilepsy duration, years, mean	16.8	12.9	18.4	12.8	15.0	12.7	15.3	12.8	13.9	12.0	13	12.4
Type of epilepsy, focal	46.7%	68.7%	54.5%	64%	48.5%	69%	53.8%	65.4%	44%	66.7%	56.3%	61.5%
Drug-resistant epilepsy	80%	41.8%	72.7%	48%	81.8%	38%	84.6%	41.0%	84%	42%	81.3%	47.4%
Number of previous ASMs, median	5	3	5	3	5	3	5	3	5	3	5	3
BRV dose, mg, median	50	100	50	100	50	100	50	100	50	100	50	100
Titration	63.3%	25.4%	63.6%	29.3%	54.5%	28.2%	57.7%	29.5%	56%	26.1%	50%	30.8%
Monotherapy	10%	32.8%	13.6%	29.3%	9.1%	36.3%	7.7%	34.6%	4%	37.7%	6.3%	33.3%
First add-on	3.3%	25.4%	4.5%	22.7%	9.1%	28.2%	7.7%	26.9%	12%	27.5%	18.8%	24.4%
Multivariate analysis
Sex, male	—		—		—		—				—
Focal epilepsy			—		—		—		—		—
Drug-resistant epilepsy	—		—
No titration period					—		—		—		—

value < 0.05. ASMs: antiseizure medications; BRV: brivaracetam; FBTCS/GTCS: focal to bilateral tonic-clonic seizures/generalized tonic-clonic seizures.